{"product_id":"kzia-vrio-analysis","title":"Kazia Therapeutics Limited (KZIA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eWhat truly separates Kazia Therapeutics Limited (KZIA) from the competition? This VRIO analysis cuts straight to the core, rigorously testing its resources for Value, Rarity, Inimitability, and Organization to pinpoint its sustainable competitive advantage. Discover the distilled summary of its strengths - or weaknesses - by reading the full findings below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKazia Therapeutics Limited (KZIA) - VRIO Analysis: Paxalisib: Brain-Penetrant PI3K\/mTOR Inhibitor Program\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core asset of Kazia Therapeutics Limited, Paxalisib, and wondering if this brain-penetrant PI3K\/mTOR inhibitor is truly a game-changer or just another biotech story. Honestly, the late-2025 clinical signals suggest it’s the former, but the path to commercialization still has hurdles.\u003c\/p\u003e\n\n\u003ch3 id=\"value\"\u003eValue: Very High Clinical and Commercial Potential\u003c\/h3\u003e\n\u003cp\u003eThe value proposition for Paxalisib is anchored by two distinct, high-need indications. For newly diagnosed, unmethylated Glioblastoma (GBM), the data from the GBM-Agile trial showed a median Overall Survival (OS) of \u003cstrong\u003e15.54 months\u003c\/strong\u003e compared to \u003cstrong\u003e11.89 months\u003c\/strong\u003e for the concurrent Standard of Care (SOC) arm. That’s a \u003cstrong\u003e3.8 month\u003c\/strong\u003e, or approximately \u003cstrong\u003e33%\u003c\/strong\u003e, improvement in OS, which is a massive signal in this disease space. Also, in advanced breast cancer, the drug showed an initial Immune-Complete Response (iCR) in a patient with metastatic TNBC when combined with pembrolizumab. Complete responses in this setting are incredibly rare, with benchmarks for even the best agents hovering around \u003cstrong\u003e0.6–4%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIt’s a clear differentiator if these signals hold up.\u003c\/p\u003e\n\u003cp\u003eHere are the key performance indicators supporting the value assessment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGBM OS Improvement:\u003c\/strong\u003e \u003cstrong\u003e33%\u003c\/strong\u003e increase in median OS in unmethylated patients.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTNBC Response:\u003c\/strong\u003e Initial iCR achieved in a single patient.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTumor Burden Reduction:\u003c\/strong\u003e \u003cstrong\u003e86%\u003c\/strong\u003e reduction in tumor burden in the TNBC patient after three weeks.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3 id=\"rarity\"\u003eRarity: A Rare Combination of Target and Delivery\u003c\/h3\u003e\n\u003cp\u003eThe rarity stems from Paxalisib’s ability to reliably cross the blood-brain barrier - a major failing point for many oncology drugs - while hitting the PI3K\/mTOR pathway. Finding a compound that achieves both, and then backs it up with a \u003cstrong\u003e33%\u003c\/strong\u003e OS lift in GBM, is uncommon. The fact that Kazia Therapeutics Limited is pursuing a standard approval pathway based on this OS data, rather than just accelerated pathways, underscores the strength of the signal they believe they have.\u003c\/p\u003e\n\n\u003ch3 id=\"imitability\"\u003eImitability: Difficult Due to Clinical Validation\u003c\/h3\u003e\n\u003cp\u003eYou can’t just buy a similar molecule and expect the same results. Imitability is difficult because it requires replicating years of development and, critically, the specific, positive clinical trial outcomes. To match the \u003cstrong\u003e15.54 months\u003c\/strong\u003e median OS result in the GBM-Agile trial, a competitor would need to run a comparable, well-designed trial and achieve the same outcome, which is a multi-year, multi-million dollar undertaking.\u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides is the proprietary knowledge around patient selection, like the focus on unmethylated GBM, which is key to unlocking that \u003cstrong\u003e33%\u003c\/strong\u003e benefit.\u003c\/p\u003e\n\n\u003ch3 id=\"organization\"\u003eOrganization: Good Financial Footing for Advancement\u003c\/h3\u003e\n\u003cp\u003eOrganization is about having the structure and capital to execute the next steps. Management is actively pushing this forward into combination trials and Phase 3 planning. Critically, in December 2025, Kazia Therapeutics secured a \u003cstrong\u003e$50 million\u003c\/strong\u003e private placement, netting approximately \u003cstrong\u003e$46.5 million\u003c\/strong\u003e. This move is designed to extend the cash runway into the second half of \u003cstrong\u003e2028\u003c\/strong\u003e, giving them the necessary runway to advance Paxalisib through pivotal studies. To be fair, their 2025 revenue was only \u003cstrong\u003e$1.83 million\u003c\/strong\u003e, showing they are still heavily reliant on financing for operations.\u003c\/p\u003e\n\u003cp\u003eHere is a quick look at the financial context supporting their current operational capacity:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (2025 Data)\u003c\/td\u003e\n\u003ctd\u003eSource Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecember 2025 Private Placement (Net Proceeds)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$46.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTo fund Paxalisib development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway End\u003c\/td\u003e\n\u003ctd\u003eSecond half of \u003cstrong\u003e2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePost-December 2025 financing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.83 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eA decrease of \u003cstrong\u003e-26.28%\u003c\/strong\u003e from the prior year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecember 31, 2024 Cash Position\u003c\/td\u003e\n\u003ctd\u003e~A$\u003cstrong\u003e3.06 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePre-2025 financing activity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3 id=\"competitive-advantage\"\u003eCompetitive Advantage: Sustained Potential\u003c\/h3\u003e\n\u003cp\u003eIf the upcoming pivotal trial data confirms the \u003cstrong\u003e33%\u003c\/strong\u003e OS signal in GBM and the combination data in breast cancer continues to mature, Paxalisib becomes a major differentiator. The combination of a brain-penetrant mechanism, strong early efficacy signals, and a secured cash runway into \u003cstrong\u003e2028\u003c\/strong\u003e positions Kazia Therapeutics for a sustained competitive advantage in specific CNS and oncology markets.\u003c\/p\u003e\n\u003cp\u003eThe next step is clear: Finance needs to finalize the pro-forma cash flow statement incorporating the December 2025 PIPE proceeds to confirm the \u003cstrong\u003e2028\u003c\/strong\u003e runway estimate. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKazia Therapeutics Limited (KZIA) - VRIO Analysis: Glioblastoma (GBM) Clinical Data Package\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe clinical data package anchors value on Overall Survival (OS) improvement in the Newly Diagnosed Unmethylated (NDU) Glioblastoma (GBM) patient subset.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAnalysis Type\u003c\/th\u003e\n\u003cth\u003ePaxalisib Median OS (Months)\u003c\/th\u003e\n\u003cth\u003eControl Group Median OS (Months)\u003c\/th\u003e\n\u003cth\u003ePatient Count (n)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGBM-AGILE Secondary Analysis (Concurrent SOC)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15.54\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.89\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNDU: Paxalisib (n=54) vs. Concurrent SOC (n=46)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGBM-AGILE Primary Analysis (Cumulative SOC)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.77\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.84\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNDU: Paxalisib (n=54) vs. Cumulative SOC (n=75)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevious Phase II Study (Historical SOC)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNDU: Paxalisib (n=27) vs. Historical Temozolomide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe secondary analysis demonstrated a 3.8-month OS improvement, equating to an approximate 33% relative improvement over the concurrent SOC arm.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003ePositive OS data in the NDU GBM population is rare, with the 3.8-month absolute improvement being a key differentiator.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe drug, paxalisib, is an oral brain-penetrant inhibitor of the PI3K\/Akt\/mTOR pathway, in-licensed from Roche AG unit Genentech.\u003c\/li\u003e\n\u003cli\u003ePaxalisib previously received Orphan Drug Designation and Fast Track Designation from the FDA for GBM in unmethylated MGMT promoter status patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe specific data set generated from the adaptive Phase II\/III GBM-AGILE study is proprietary to the trial sponsors and Kazia.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe GBM-AGILE trial is sponsored by the Global Coalition for Adaptive Research (GCAR).\u003c\/li\u003e\n\u003cli\u003eThe trial utilized complex innovative design principles, including Bayesian principles applied to the primary endpoint (Overall Survival).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe organization is focused on leveraging the data for regulatory submission, although the initial pathway has been clarified.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFollowing the July 2024 announcement, Kazia stated it would request an FDA meeting to discuss an accelerated approval pathway.\u003c\/li\u003e\n\u003cli\u003eThe FDA indicated that the OS data would not be appropriate for an accelerated pathway, necessitating a registrational Phase III trial.\u003c\/li\u003e\n\u003cli\u003eThe company reached alignment with the FDA on key aspects of a proposed pivotal study design, including patient population, primary endpoint, and comparator arm.\u003c\/li\u003e\n\u003cli\u003eKazia expects to outline its path forward by the end of January 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe sustained advantage is derived from the established, albeit secondary, positive OS signal in a high-unmet-need population, forming the basis for the next pivotal trial.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe stock surged by 260% on July 10, 2024, following the data release.\u003c\/li\u003e\n\u003cli\u003eThe company secured a $50 million private placement, expected to extend its cash runway into the second half of 2028.\u003c\/li\u003e\n\u003cli\u003eThe Market Cap as of December 5, 2025, was $USD143.60M.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKazia Therapeutics Limited (KZIA) - VRIO Analysis: Strategic Financing Capability (December 2025 PIPE)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe financing was a $50.0 million private placement of equity securities. The expected net proceeds to the Company were approximately $46.5 million after deducting placement agent's fees and estimated offering expenses. This capital is expected to extend the cash runway into the second half of 2028, combined with existing cash and cash equivalents.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Financing Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Net Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$46.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice Per ADS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Extended To\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eH2 2028\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransaction Closing Date (Expected)\u003c\/td\u003e\n\u003ctd\u003eDecember 3, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe financing was secured while the Company faced a staff determination letter on November 12, 2025, regarding compliance with Nasdaq's listing standards due to market value being below the required minimum. The Company reported that the proceeds are expected to enhance stockholders' equity to exceed the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1). At the time of announcement, the Company's market capitalization was $16.79 million, and the current ratio stood at 0.35.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe transaction was led by a syndicate of healthcare-dedicated institutional and accredited investors.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdar1 Capital Management LLC\u003c\/li\u003e\n\u003cli\u003eIkarian Capital LLC\u003c\/li\u003e\n\u003cli\u003eStonepine Capital Management\u003c\/li\u003e\n\u003cli\u003eVelan Capital Investment Management LP\u003c\/li\u003e\n\u003cli\u003eRevach Capital Management, LLC\u003c\/li\u003e\n\u003cli\u003eExisting shareholders, including Jorey Chernett\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nKonik Capital Partners, LLC acted as the exclusive placement agent.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nManagement executed the Securities Purchase Agreements for the private placement. The intended use of the net proceeds includes:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSupport the continued clinical development of lead program paxalisib.\u003c\/li\u003e\n\u003cli\u003eAdvancing the PD-L1 degrader program.\u003c\/li\u003e\n\u003cli\u003eGeneral corporate purposes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nThe financing was structured as a straightforward equity investment with no common warrant coverage.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe capital injection provides financial stability, extending operational capacity past 2027 into the second half of 2028.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKazia Therapeutics Limited (KZIA) - VRIO Analysis: Exclusive QIMR Berghofer Combination Therapy IP License\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: High\u003c\/strong\u003e; secures exclusive rights to combine paxalisib with immunotherapy\/PARP inhibitors, broadening its application beyond monotherapy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe license covers the development of any drugs or product candidates within the PI3K inhibitor class in combination with immunotherapy or PARP inhibitors.\u003c\/li\u003e\n\u003cli\u003ePreliminary results from the first patient in the Phase 1b trial combining Paxalisib, pembrolizumab (Keytruda®), and chemotherapy showed a \u003cstrong\u003e\u0026gt;50% reduction\u003c\/strong\u003e in circulating tumor cells (CTCs) after 21 days (End-of-Cycle 1).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Rare\u003c\/strong\u003e; an exclusive, worldwide license from a top research center for a specific, high-potential combination strategy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe agreement is an exclusive, worldwide, sub-licensable and royalty-bearing license from QIMR Berghofer Medical Research Institute.\u003c\/li\u003e\n\u003cli\u003eThe collaboration leading to the license began in December 2022.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Difficult\u003c\/strong\u003e; the exclusivity prevents direct imitation of the licensed combination claims.\u003c\/p\u003e\n\u003cp\u003eThe exclusivity granted prevents direct imitation of the licensed combination claims for PI3K inhibitors with immunotherapy or PARP inhibitors.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Good\u003c\/strong\u003e; this IP is being actively tested in new trials, like the advanced breast cancer study.\u003c\/p\u003e\n\u003cp\u003eThe license terms include standard provisions for development milestones related to the initiation of Phase 1, Phase 2 trial, first Phase 3 trial, and first product approval.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\/Term\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Source\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense Partner\u003c\/td\u003e\n\u003ctd\u003eQIMR Berghofer Medical Research Institute\u003c\/td\u003e\n\u003ctd\u003eOne of Australia's foremost cancer research centres.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense Scope\u003c\/td\u003e\n\u003ctd\u003eExclusive, worldwide, sub-licensable and royalty-bearing\u003c\/td\u003e\n\u003ctd\u003eFor PI3K inhibitor drug combinations with immunotherapy or PARP inhibitors.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombination Trial Efficacy (Brain Mets)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e67%\u003c\/strong\u003e Partial Response (PR)\u003c\/td\u003e\n\u003ctd\u003eObserved in patients receiving paxalisib at 45mg daily with radiotherapy (Part II of Phase 1 study, n=17 evaluable).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical Comparator (WBRT)\u003c\/td\u003e\n\u003ctd\u003e20-45% Overall Response Rates\u003c\/td\u003e\n\u003ctd\u003eHistorical efficacy for Whole Brain Radiotherapy (WBRT) alone for brain metastases.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Market Capitalization\u003c\/td\u003e\n\u003ctd\u003eApproximately $15.28 million\u003c\/td\u003e\n\u003ctd\u003eCurrent market valuation context for KZIA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest Reported Revenue (FY2025)\u003c\/td\u003e\n\u003ctd\u003e$0.03 million (Operating Revenue)\u003c\/td\u003e\n\u003ctd\u003eLatest reported revenue figure in millions AUD.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained\u003c\/strong\u003e; as long as the license is in effect, competitors cannot use this specific combination strategy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe license grants potential intellectual property rights around PI3K inhibitors for novel therapeutics in solid tumours, such as breast cancer.\u003c\/li\u003e\n\u003cli\u003ePaxalisib's lead program is a PI3K inhibitor.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKazia Therapeutics Limited (KZIA) - VRIO Analysis: FDA Regulatory Designations for Paxalisib\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High; Potential value from a Pediatric Priority Review Voucher (pPRV) associated with Rare Pediatric Disease Designation (RPDD) has historically commanded prices exceeding \u003cstrong\u003eUS$100 million\u003c\/strong\u003e (or \u003cstrong\u003eA$147 million\u003c\/strong\u003e). Orphan Drug Designation (ODD) includes a waiver of Prescription Drug User Fees Act (PDUFA fees), which were over \u003cstrong\u003eUS$3 million\u003c\/strong\u003e in FY2022.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; Designations are granted for drugs addressing rare diseases, such as Atypical Teratoid\/Rhabdoid Tumors (AT\/RT) and Diffuse Intrinsic Pontine Glioma (DIPG).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Impossible; These designations are granted exclusively by the FDA regulatory body, not developed internally.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; Management is clearly focused on regulatory strategy, seeking alignment with the FDA Oncology Center of Excellence’s Project FrontRunner initiative. This strategy is supported by clinical data showing median Overall Survival (OS) of \u003cstrong\u003e15.54 months\u003c\/strong\u003e ($n=54$) in newly diagnosed unmethylated GBM patients treated with paxalisib versus \u003cstrong\u003e11.89 months\u003c\/strong\u003e ($n=46$) for concurrent standard of care (SOC). This represents a \u003cstrong\u003e3.8-month\u003c\/strong\u003e improvement in OS, or a \u003cstrong\u003e33%\u003c\/strong\u003e improvement.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; ODD can provide up to \u003cstrong\u003e7.5 years\u003c\/strong\u003e of Orphan Drug Exclusivity (ODE).\u003c\/p\u003e\n\n\u003cp\u003eThe specific FDA Regulatory Designations granted for Paxalisib include:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDesignation\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eDate Granted (Approximate)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan Drug Designation (ODD)\u003c\/td\u003e\n\u003ctd\u003eGlioblastoma\u003c\/td\u003e\n\u003ctd\u003eFebruary 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFast Track Designation (FTD)\u003c\/td\u003e\n\u003ctd\u003eGlioblastoma\u003c\/td\u003e\n\u003ctd\u003eAugust 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare Pediatric Disease Designation (RPDD)\u003c\/td\u003e\n\u003ctd\u003eDiffuse Intrinsic Pontine Glioma (DIPG)\u003c\/td\u003e\n\u003ctd\u003eAugust 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan Drug Designation (ODD)\u003c\/td\u003e\n\u003ctd\u003eAtypical Teratoid\/Rhabdoid Tumors (AT\/RT)\u003c\/td\u003e\n\u003ctd\u003eJune 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare Pediatric Disease Designation (RPDD)\u003c\/td\u003e\n\u003ctd\u003eAtypical Teratoid\/Rhabdoid Tumors (AT\/RT)\u003c\/td\u003e\n\u003ctd\u003eJune 2022 or July 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFast Track Designation (FTD)\u003c\/td\u003e\n\u003ctd\u003eSolid Tumor Brain Metastases (with radiation therapy)\u003c\/td\u003e\n\u003ctd\u003eJuly 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe development program for paxalisib has involved a completed Phase 2\/3 study in glioblastoma (GBM-Agile). The company secured a \u003cstrong\u003e$50 million\u003c\/strong\u003e private placement, with proceeds expected to extend the cash runway into the second half of \u003cstrong\u003e2028\u003c\/strong\u003e. The purchase price in this financing was equivalent to \u003cstrong\u003e$5.00\u003c\/strong\u003e per ADS, where each ADS represents \u003cstrong\u003e500\u003c\/strong\u003e ordinary shares.\u003c\/p\u003e\n\n\u003cp\u003eFurther details on the regulatory pathway and prior trial data include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePaxalisib has been the subject of \u003cstrong\u003eten\u003c\/strong\u003e clinical trials in glioblastoma.\u003c\/li\u003e\n\u003cli\u003eIn a prior Phase II trial for GBM, progression-free survival (PFS) was \u003cstrong\u003e8.5 months\u003c\/strong\u003e compared to \u003cstrong\u003e5.3 months\u003c\/strong\u003e for standard-of-care drug temozolomide.\u003c\/li\u003e\n\u003cli\u003eThe company is planning a post-approval, randomized Phase 3 confirmatory study prior to New Drug Application (NDA) submission, aligning with Project FrontRunner principles.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKazia Therapeutics Limited (KZIA) - VRIO Analysis: EVT801: Selective VEGFR3 Inhibitor Program\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eEVT801: Selective VEGFR3 Inhibitor Program\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: Moderate; it’s the second differentiated asset, with Phase 1 for advanced solid tumors now complete.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 Completion Status\u003c\/td\u003e\n\u003ctd\u003eStage 1 successfully met primary and secondary objectives.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximal Tolerated Dose (MTD)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e500mg\u003c\/strong\u003e twice a day (BID)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecommended Phase 2 Dose (RP2D)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e400mg\u003c\/strong\u003e BID (for continuous monotherapy)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patients Treated (Stage 1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Cohorts\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e (ranging from \u003cstrong\u003e50mg\u003c\/strong\u003e once daily (QD) to \u003cstrong\u003e500mg\u003c\/strong\u003e BID)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevalent Indication\u003c\/td\u003e\n\u003ctd\u003eAdvanced Ovarian Cancer (\u003cstrong\u003e11\u003c\/strong\u003e patients)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRarity: Moderate; a selective VEGFR3 inhibitor is a less common target in the current pipeline landscape.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eEVT801 is the only inhibitor known to inhibit both VEGFR-3 homodimers and VEGFR-3:VEGFR-2 heterodimers.\u003c\/li\u003e\n\u003cli\u003eIt shows low nanomolar inhibitory activity and high selectivity over kinases, various receptors, and ion channels.\u003c\/li\u003e\n\u003cli\u003eIt is a highly selective small molecule VEGFR3 tyrosine kinase inhibitor targeting tumour angiogenesis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eImitability: Moderate; less advanced than paxalisib, but still requires specific scientific know-how to develop.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eEVT801 was licensed from Evotec SE in \u003cstrong\u003eApril 2021\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe compound is currently in \u003cstrong\u003ePhase I\u003c\/strong\u003e clinical development.\u003c\/li\u003e\n\u003cli\u003ePreclinical data showed evidence of synergy with immuno-oncology agents.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOrganization: Good; the completion of Phase 1 follow-up shows steady execution.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe Safety Review Team (SRT) unanimously agreed on the MTD.\u003c\/li\u003e\n\u003cli\u003ePreliminary data presented at the 15th Biennial Ovarian Cancer Research Symposium in \u003cstrong\u003eSeptember 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Phase I study employed a rich suite of biomarkers analysis using histology, transcriptomics and immunomonitoring.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCompetitive Advantage: Temporary; its value is currently speculative until later-stage data emerges.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication Subset\u003c\/th\u003e\n\u003cth\u003eActivity Metric\u003c\/th\u003e\n\u003cth\u003eResult\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOvarian Cancer Patients\u003c\/td\u003e\n\u003ctd\u003eStable Disease or Better (for at least \u003cstrong\u003e3\u003c\/strong\u003e cycles)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOvarian Cancer Patients\u003c\/td\u003e\n\u003ctd\u003ePartial Response (after \u003cstrong\u003e2\u003c\/strong\u003e cycles)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e patient (-\u003cstrong\u003e39%\u003c\/strong\u003e decrease)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrolled Patients (Total)\u003c\/td\u003e\n\u003ctd\u003eNumber of different cancer types\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAssociated Financial Data (KZIA):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eMarket capitalization: \u003cstrong\u003e$22.35 M USD\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRevenue (FY): \u003cstrong\u003e$27.20 K USD\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet income (FY): \u003cstrong\u003e$-13.41 M USD\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eBasic EPS (TTM): \u003cstrong\u003e$-12.31 USD\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eShares Float: \u003cstrong\u003e10.58M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eKazia Therapeutics Limited (KZIA) - VRIO Analysis: Lean Virtual Pharma Operating Model\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe structure is designed to maximize R\u0026amp;D impact, with the stated goal of approximately \u003cstrong\u003e75%\u003c\/strong\u003e of cashflows directed into clinical trials.\u003c\/p\u003e\n\u003cp\u003eFinancial context supporting capital-light R\u0026amp;D focus:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY2025 Sales: \u003cstrong\u003eAUD 0.042 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY2025 Net Loss: \u003cstrong\u003eAUD 20.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash from Operating Activities FY2024: \u003cstrong\u003e-AUD 9.58 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe execution of the virtual model, characterized by a minimal internal team, is key to its efficiency compared to industry norms.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eKazia Therapeutics (KZIA)\u003c\/th\u003e\n\u003cth\u003eIndustry Benchmark (Biotech)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees (Latest Reported)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e (as of Jun 29, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e11-50\u003c\/strong\u003e (General Range)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAUD 0.042 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eVaries Significantly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Founded\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1994\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eVaries Significantly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Exchange Listing\u003c\/td\u003e\n\u003ctd\u003eNASDAQCM (ADRs)\u003c\/td\u003e\n\u003ctd\u003eNASDAQ\/ASX\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eReplicating the established network and scientific validation requires time and resources.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLead Program: paxalisib, Orphan Drug Designation (US FDA) for glioblastoma.\u003c\/li\u003e\n\u003cli\u003eSecond Asset: EVT801, under development for advanced cancer.\u003c\/li\u003e\n\u003cli\u003eTrack Record: Demonstrated ability to realize value through partnering, both inbound and outbound.\u003c\/li\u003e\n\u003cli\u003eRecent Capital Raise: \u003cstrong\u003e$50.0 Million\u003c\/strong\u003e Private Placement announced December 2, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe model is fundamental to the capital-light strategy, evidenced by the low sales base and reliance on financing to fund R\u0026amp;D activities.\u003c\/p\u003e\n\u003cp\u003eFinancial Position Snapshot (FY2025 Context):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY2025 Sales: \u003cstrong\u003eAUD 0.042 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Change in Cash FY2025: \u003cstrong\u003e2.69 million\u003c\/strong\u003e (AUD).\u003c\/li\u003e\n\u003cli\u003eCash from Financing Activities FY2024: \u003cstrong\u003e5.99 million\u003c\/strong\u003e (AUD).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThe efficiency is most potent before late-stage commercialization, as evidenced by the current market capitalization context.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Cap\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$18.456m\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSnapshot of valuation prior to late-stage commercialization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.83m\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBasis for per-share metrics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiluted EPS (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-18.705\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflects pre-revenue\/development stage financials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Growth YOY\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-27.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflects year-over-year sales fluctuation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eKazia Therapeutics Limited (KZIA) - VRIO Analysis: New PD-L1 Protein Degrader Program\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis of the New PD-L1 Protein Degrader Program (NDL2) asset, in-licensed on \u003cstrong\u003eOctober 7, 2025\u003c\/strong\u003e, against the VRIO framework is detailed below, incorporating relevant financial and statistical data.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment Implication\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eFuture potential; diversifies the pipeline into a novel mechanism, reducing reliance on the two existing assets.\u003c\/td\u003e\n\u003ctd\u003eOne-time in-licensing payment of approximately \u003cstrong\u003e$1.39 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eRare; being a first-in-class program implies proprietary early-stage science.\u003c\/td\u003e\n\u003ctd\u003eNovel bicyclic peptide degrader targeting post-translationally modified PD-L1 forms.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult; being first-to-market with a novel mechanism is hard to copy quickly.\u003c\/td\u003e\n\u003ctd\u003ePreclinical models showed significant tumor growth reduction in TNBC as monotherapy and in combination with anti-PD-1 therapies, with \u003cstrong\u003eno toxicity observed to date\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eGood; the October 2025 in-licensing shows active business development to build out the portfolio.\u003c\/td\u003e\n\u003ctd\u003eSubsequent financing of \u003cstrong\u003e$50.0 million\u003c\/strong\u003e (Gross) \/ \u003cstrong\u003e$46.5 million\u003c\/strong\u003e (Net Proceeds) intended to advance this program.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary; this advantage will erode as other degrader programs advance.\u003c\/td\u003e\n\u003ctd\u003eFinancing is expected to extend cash runway into the second half of \u003cstrong\u003e2028\u003c\/strong\u003e to support advancement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe program's strategic fit is supported by the intent to explore synergistic opportunities with existing pipeline assets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003epaxalisib\u003c\/strong\u003e (PI3K\/mTOR inhibitor)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEVT801\u003c\/strong\u003e (selective VEGFR3 inhibitor)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe initial commitment for the asset was:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOne-time payment: \u003cstrong\u003e$1.39 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFuture obligation: Share of commercialization revenue, including out-licensing payments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKazia Therapeutics Limited (KZIA) - VRIO Analysis: Exclusive In-License from Genentech (Paxalisib Origin)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eExclusive In-License from Genentech (Paxalisib Origin)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High; provides immediate access to a molecule with established safety data from a major pharma company, skipping early-stage risk.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; securing a high-potential asset from a company like Genentech is a significant sourcing win.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; the original asset and the in-license terms are locked down.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; the entire company strategy has been built around optimizing this asset since late \u003cstrong\u003e2016\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the rights to paxalisib are secured for the development life of the drug.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Proceeds from Private Placement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$46.50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-December 2025 Financing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway End Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eH2 2028\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-December 2025 Financing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAUD 0.042 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY Ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAUD 20.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY Ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003ePaxalisib (originally GDC-0084) licensed in October \u003cstrong\u003e2016\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePaxalisib has been the subject of \u003cstrong\u003eten\u003c\/strong\u003e clinical trials.\u003c\/li\u003e\n\u003cli\u003eMedian Overall Survival in Glioblastoma: \u003cstrong\u003e15.7 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEstimated Glioblastoma Annual Commercial Market: US$ \u003cstrong\u003e1.5 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUpfront Payment for Sovargen CNS License: US$ \u003cstrong\u003e1.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePotential Milestone Payments for Sovargen CNS License: Up to US$ \u003cstrong\u003e19 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eQ4 2025 Cash Burn vs. Runway Projection:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCash Runway Projected To: \u003cstrong\u003eH2 2028\u003c\/strong\u003e\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516196708501,"sku":"kzia-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/kzia-vrio-analysis.png?v=1740187856","url":"https:\/\/dcf-model.com\/pt\/products\/kzia-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}